Sign Up Today and Learn More About Compass Therapeutics Stock
Invest in or calculate the value of your shares in Compass Therapeutics or other pre-IPO companies through EquityZen's platform.
Compass Therapeutics Stock
Compass Therapeutics is a biopharmaceutical company focused on drugging the immune system to treat human diseases.
About Compass Therapeutics Stock
Founded
2014
Headquarters
Cambridge, MA, US
Total Funding
116M
Industries
Science and Engineering, Health Care, Biotechnology
We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures.
Compass Therapeutics Press Mentions
Stay in the know about the latest news on Compass Therapeutics
Compass Therapeutics Adds $49 Million to Series A
Wall Streets Journal • Jul 12, 2018
Compass Therapeutics Management
Leadership team at Compass Therapeutics
CEO
Thomas Schuetz
Co-Founder, President/COO
Errik Anderson
Join now and verify your accreditation status to gain access to:
- Compass Therapeutics Current Valuation
- Compass Therapeutics Stock Price
- Compass Therapeutics Management
- Available deals in Compass Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Compass Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Compass Therapeutics Revenue and Financials
- Compass Therapeutics Highlights
- Compass Therapeutics Business Model
- Compass Therapeutics Risk Factors
- Compass Therapeutics Research Report from SACRA Research
Trading Compass Therapeutics Stock
How to invest in Compass Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Compass Therapeutics through EquityZen funds. These investments are made available by existing Compass Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Compass Therapeutics stock?
Shareholders can sell their Compass Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."